Haleos logo

Haleos

HALEOSLABS NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹437 Cr
Volatility
Moderate
P/E Ratio
27.96
EBITDA
₹44.67 Cr
Return on Equity
8.83%
Debt to Equity
0.52
Book Value
₹706.33
52W High
₹1,774
52W Low
₹1,091.1

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Weaknesses

3
  • The company has delivered a poor sales growth of 4.68% over past five years.
  • Company has a low return on equity of 8.24% over last 3 years.
  • Company might be capitalizing the interest cost

Growth Rate

Revenue Growth
-4.52% lower than 3Y
Net Income Growth
6.31% lower than 3Y
Cash Flow Change
40.11% lower than 3Y
ROE
170% higher than 3Y
ROCE
73.19% higher than 3Y
EBITDA Margin (Avg.)
-6.87% lower than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
74.65
69.26
72.05
89.99
92.55
78.46
84.6
89.11
82.5
81.37
94.78
75.14
72.94
Expenses
72.11
61.33
62.75
78.63
76.27
69.89
71.85
81.69
70.79
67.79
80.73
70.98
63.82
Operating Profit
2.54
7.93
9.3
11.36
16.28
8.57
12.75
7.42
11.71
13.58
14.05
4.16
9.12
OPM %
3.4%
11.45%
12.91%
12.62%
17.59%
10.92%
15.07%
8.33%
14.19%
16.69%
14.82%
5.54%
12.5%
Other Income
0.61
0.27
0.58
2.36
0.44
2.04
0.06
2.34
1
0.42
0.18
2.01
0.46
Interest
2.18
2.81
2.34
2.84
2.4
2.14
2.14
2.03
1.87
1.62
1.54
1.42
1.9
Depreciation
3.7
3.73
3.73
3.78
3.68
3.76
3.76
3.8
3.82
3.89
3.91
3.85
4.24
PBT
-2.73
1.66
3.81
7.1
10.64
4.71
6.91
3.93
7.02
8.49
8.78
0.9
3.44
Tax %
40.29%
126.51%
-8.14%
8.73%
33.27%
29.72%
29.81%
11.45%
37.61%
24.38%
24.26%
62.22%
46.51%
Net Profit
-3.83
-0.44
4.12
6.47
7.1
3.3
4.86
3.48
4.39
6.42
6.65
0.35
1.84
EPS in Rs
-5.95
2.25
14.22
19.52
23.15
15.45
18.09
9.82
13.76
20.18
21.9
1.46
8.77
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
378
261
266
350
316
306
345
334
324
Expenses
343
235
235
316
287
275
300
289
283
Operating Profit
35
25
30
35
29
31
45
45
41
OPM %
9%
10%
11%
10%
9%
10%
13%
13%
13%
Other Income
2
2
2
14
5
4
5
2
3
Interest
6
5
5
6
7
10
9
6
6
Depreciation
6
8
8
10
11
15
15
15
16
PBT
25
15
20
33
17
10
26
25
22
Tax %
30%
31%
31%
23%
31%
36%
28%
29%
—
Net Profit
18
10
14
25
11
6
19
18
15
EPS in Rs
59.04
33.67
44.85
83.75
37.91
30.07
66.52
57.26
52.31
Div. Payout %
3%
0%
3%
2%
4%
5%
2%
3%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
3
3
3
3
3
3
3
3
Reserves
103
113
126
149
166
174
194
211
Borrowings
47
65
65
80
100
101
86
111
Other Liabilities
116
72
108
125
126
114
107
130
Total Liabilities
270
253
302
357
395
391
390
454
Fixed Assets
118
124
130
142
228
223
232
268
CWIP
3
16
38
51
1
6
0
10
Investments
0
0
0
0
0
0
0
0
Other Assets
148
113
134
164
166
162
158
176
Total Assets
270
253
302
357
395
391
390
454
Figures in ₹ Crores

Cash Flow

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
30
15
35
-11
15
24
34
37
Investing
-44
-27
-26
-7
-31
-18
-15
-58
Financing
15
12
-3
11
17
-7
-19
21
Net Cash Flow
1
0
6
-8
0
-1
0
1
Free Cash Flow
6
-9
0
-53
-28
4
19
-21
CFO/OP
105
69
133
-10
62
88
94
98
Figures in ₹ Crores

Ratios

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
40
30
47
35
53
61
73
67
Inventory Days
116
149
164
159
184
196
160
210
Days Payable
140
101
163
146
127
143
126
162
Cash Conversion Cycle
16
78
48
48
110
115
106
116
Working Capital Days
14
18
2
17
24
11
7
5
ROCE %
—
12%
13%
12%
8%
7%
12%
10%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Haleos insights

67 extracted metrics + investor summaries across FY16–FY26.

Log in — free

Shareholding Pattern

DIIs0.31%Promot.72.11%Others3.59%Public23.99%As ofJun 2026

Documents

Frequently Asked Questions about Haleos

What does Haleos Labs Limited do?
Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates[1]
Where is Haleos Labs Limited (HALEOSLABS) listed?
Haleos Labs Limited trades as HALEOSLABS on the NSE and under code 540679 on the BSE.
Which sector does Haleos Labs Limited belong to?
Haleos Labs Limited is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Haleos Labs Limited?
Haleos Labs Limited has a market capitalisation of ₹437.47 Cr, which places it in the Small Cap band.
What is the PE ratio of Haleos Labs Limited?
Haleos Labs Limited trades at a PE ratio of 27.96, against a book value of ₹706.33 per share.
What is the 52-week high and low of Haleos Labs Limited?
Over the last 52 weeks Haleos Labs Limited has traded between ₹1,091.1 and ₹1,774.
Does Haleos Labs Limited pay dividends?
Haleos Labs Limited has a dividend yield of 0.10%.
What is the Return on Equity (ROE) of Haleos Labs Limited?
Haleos Labs Limited reported a return on equity of 8.83%. Its debt-to-equity ratio is 0.52.

Company Information

Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates[1]

Website haleoslabs.com
CEO Mr. Talluri Veera Venkata Satyanarayana Murthy
Employees 592
Listed 2017-08-17
Face Value ₹ 10
Issued Size 30,23,287

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/HALEOSLABS.md for Haleos Labs Limited: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List